A randomized trial of intravesical doxorubicin and immunotherapy with bacille calmette-guérin for transitional-cell carcinoma of the bladder

New England Journal of Medicine

Volumn 325, Issue 17, 1991, Pages 1205-1209

  Lamm, Donald L ^a   Blumenstein, Brent A ^b   Crawford, E David ^c   Montie, James E ^d   Scardino, Peter ^e   Grossman, H Barton ^f   Stanisic, Thomas H ^g   Smith, Joseph A ^h   Sullivan, Jerry ⁱ   Sarosdy, Michael F ^j   Crissman, John D ^k   Coltman, Charles A ^l  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g UNIVERSITY OF ARIZONA   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k HENRY FORD HOSPITAL   (United States)

^l Southwest Oncology Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN;

ADULT; ADVERSE DRUG REACTION; AGED; BLADDER CARCINOMA; CANCER RECURRENCE; CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; TRANSITIONAL CELL CARCINOMA;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BLADDER NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; COMPARATIVE STUDY; DOXORUBICIN; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MIDDLE AGE; MYCOBACTERIUM BOVIS; NEOPLASM RECURRENCE, LOCAL; RANDOM ALLOCATION; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE;

EID: 0026004545     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199110243251703     Document Type: Article

References (23)

1. Lamm DL, Thor DE, Stogdill VD, Radwin HM. Bladder cancer immunotherapy. J Urol 1982; 128: 931–5.
2. Pinsky CM, Camacho F, Kerr D, Braun DW Jr, Whitmore WF Jr, Oettgen HF. Treatment of superficial bladder cancer with intravesical BCG. In: Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Excerpta Medica, 1982:309–13.
3. Morales A, Eidinger D, Bruce AW. Intracavity bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180–3.
4. Brosman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder cancer. J Urol 1982; 128: 27–30.
5. Adolphs HD, Bastian HP. Chemoimmune prophylaxis of superficial bladder tumors. J Urol 1983; 129: 29–32.
6. Schellhammer PF, Ladaga LE, Fillion MB. Bacillus Calmette-Guerin for therapy of superficial transitional cell carcinoma of the bladder. J Urol 1986; 135: 261–4.
7. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987; 137: 220–4.
8. Herr HW, Laudone VP, Whitmore WF Jr. An overview of intravesical therapy for superficial bladder tumors. J Urol 1987; 138: 1363–8.
9. Martinez-Pineiro JA, Jimenez-Leone JS, Martinez-Pineiro L Jr, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990; 143: 502–7.
10. Lamm DL. Immunotherapy versus chemotherapy in the treatment of superficial bladder cancer. In: Bloom HFK, Hanham IWF, eds. Urology oncology: dilemmas and developments. Chichester, England: John Wiley, 1988: 107–17.
11. Garnick MB, Schade D, Israel M, Maxwell B, Richie JP. Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma. J Urol 1984; 131: 43–6.
12. Edsmyr F, Andersson L. Chemotherapy in bladder carcinoma. Urol Res 1978; 6: 263–4.
13. Jakse G, Hofstadter F, Marberger H. Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J Urol 1981; 125: 185–90.
14. Kowalkowski TS, Lamm DL. Intravesical therapy of superficial bladder cancer. In: Resnick MI, ed. Current trend in urology. Baltimore: Williams & Wilkins, 1988:89–107.
15. Koss LG. Tumors of the urinary bladder. Atlas of tumor pathology. 2nd series. Fascicle 11. Washington, D.C.: Armed Forces Institute of Pathology, 1975.
16. Anderson A, Auquier A, Hauck WW, Oakes D, Vandaele W, Weisberg HI. Statistical methods for comparative studies: techniques for bias reduction. New York: John Wiley, 1980.
17. Rawls WH, Lamm DL, Lowe BA, et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol 1990; 144: 1328–30.
18. Deresiewicz RL, Stone RM, Aster JC. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J Urol 1990; 144: 1331–4.
19. Reitsma DJ, Guinan P, Lamm Dl, et al. Long-term effect of intravesical Bacillus Calmette-Guerin (BCG) Tice strain on flat carcinoma in situ of the bladder. In: Debruyne FMJ, Denis L, van der Meijden APM, eds. BCG in superficial bladder cancer. Vol. 310 of Progress in clinical and biological research. New York: Alan R. Liss, 1989:171–85.
20. Herr HW, Laudone VP, Badalament RA, et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450–5.
21. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1983; 127: 250–2.
22. Kalish LA, Garnick MB, Richie JP. Appropriate endpoints for superficial bladder cancer clinical trials. J Clin Oncol 1987; 5: 2004–8.
23. Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedell GH. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 1983; 130: 677–80.